Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes
暂无分享,去创建一个
[1] Maolin Lu,et al. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants , 2022, Viruses.
[2] An Wang,et al. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction , 2022, Communications Biology.
[3] A. Takada,et al. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection , 2022, Microbiology spectrum.
[4] J. Kamil,et al. Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein , 2022, mBio.
[5] S. K. Janaka,et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection , 2022, PloS one.
[6] P. Fournier,et al. Culture and identification of a “Deltamicron” SARS‐CoV‐2 in a three cases cluster in southern France , 2022, medRxiv.
[7] S. Karmakar,et al. Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective , 2022, Journal of the Indian Institute of Science.
[8] P. Fournier,et al. Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France , 2022, Archives of Virology.
[9] P. Fournier,et al. Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021 , 2022, Journal of medical virology.
[10] B. La Scola,et al. The puzzling mutational landscape of the SARS‐2‐variant Omicron , 2022, Journal of medical virology.
[11] A. Shukla,et al. Antibody-dependent enhancement of virus infection and disease: implications in COVID-19 , 2022, Journal of basic and clinical physiology and pharmacology.
[12] P. Colson,et al. The emergence, dynamics and significance of SARS-CoV-2 variants , 2022, New Microbes and New Infections.
[13] P. Zhou,et al. Antibody-Dependent Enhancement of SARS-CoV-2 Infection of Human Immune Cells: In Vitro Assessment Provides Insight in COVID-19 Pathogenesis , 2021, Viruses.
[14] T. Shioda,et al. The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production , 2021, Scientific Reports.
[15] Zhancheng Gao,et al. Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS , 2021, Frontiers in Cellular and Infection Microbiology.
[16] D. Wesemann,et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant , 2021, Science.
[17] S. Subramanian,et al. Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States , 2021, European Journal of Epidemiology.
[18] D. Barh,et al. Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution , 2021, Environmental Research.
[19] Yang Li,et al. Antibody dependent enhancement: Unavoidable problems in vaccine development , 2021, Advances in Immunology.
[20] L. Du,et al. Neutralizing antibodies for the prevention and treatment of COVID-19 , 2021, Cellular & Molecular Immunology.
[21] A. Iwasaki,et al. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants , 2021, Cell.
[22] G. R. Schleder,et al. Structural dynamics of SARS-CoV-2 nucleocapsid protein induced by RNA binding , 2021, bioRxiv.
[23] S. Madhi,et al. Emergence and phenotypic characterization of C.1.2, a globally detected lineage that rapidly accumulated mutations of concern , 2021 .
[24] D. Standley,et al. The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines , 2021, bioRxiv.
[25] R. Ruprecht,et al. Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection , 2021, AIDS.
[26] Y. Liu,et al. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.
[27] J. Fantini,et al. Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia , 2021, Journal of Infection.
[28] D. Barh,et al. Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function , 2021, International Journal of Biological Macromolecules.
[29] X. Xia. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines , 2021, Vaccines.
[30] C. Woods,et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.
[31] W. Niu,et al. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection , 2021, iScience.
[32] J. Fantini,et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks , 2021, Journal of Infection.
[33] J. Nielsen,et al. Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups , 2021, medRxiv.
[34] William T. Harvey,et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 , 2021, Cell Reports.
[35] D. Standley,et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies , 2021, Cell.
[36] D. Barh,et al. Implications derived from S-protein variants of SARS-CoV-2 from six continents , 2021, bioRxiv.
[37] H. Schuitemaker,et al. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease , 2021, NPJ vaccines.
[38] V. Gordeliy,et al. Structure and dynamics of the SARS-CoV-2 envelope protein monomer , 2021, bioRxiv.
[39] S. Rowland-Jones,et al. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design , 2020, Biochemical and Biophysical Research Communications.
[40] R. Shukla,et al. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine , 2020, Frontiers in Cellular and Infection Microbiology.
[41] J. Fantini,et al. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19 , 2020, Biochemical and Biophysical Research Communications.
[42] S. Tripathi,et al. Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection , 2020, Frontiers in Cellular and Infection Microbiology.
[43] Peter B Rosenthal,et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.
[44] Yifan Cheng,et al. Antibody-dependent enhancement of coronavirus , 2020, International Journal of Infectious Diseases.
[45] S. Rowland-Jones,et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.
[46] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[47] Eric J Yager. Antibody-dependent enhancement and COVID-19: Moving toward acquittal , 2020, Clinical Immunology.
[48] J. Fantini,et al. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal , 2020, International Journal of Antimicrobial Agents.
[49] A. Iwasaki,et al. The potential danger of suboptimal antibody responses in COVID-19 , 2020, Nature Reviews Immunology.
[50] E. Ooi,et al. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development , 2020, EBioMedicine.
[51] Jacques Fantini,et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.
[52] Shibo Jiang,et al. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees , 2020, Nature.
[53] Jason A. Tetro,et al. Is COVID-19 receiving ADE from other coronaviruses? , 2020, Microbes and Infection.
[54] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[55] Fang Li,et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.
[56] R. Kulkarni. Antibody-Dependent Enhancement of Viral Infections , 2019, Dynamics of Immune Activation in Viral Diseases.
[57] H. Turner,et al. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics , 2019, Proceedings of the National Academy of Sciences.
[58] T. Takano,et al. Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route , 2019, The Journal of veterinary medical science.
[59] S. Varga,et al. The CD8 T Cell Response to Respiratory Virus Infections , 2018, Front. Immunol..
[60] A. García-Sastre,et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity , 2017, Science.
[61] J. Taubenberger,et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.
[62] G. Screaton,et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus , 2016, Nature Immunology.
[63] Krishna Shankara Narayanan,et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.
[64] Jing Xie,et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.
[65] T. Takano,et al. Mutation of neutralizing/antibody-dependent enhancing epitope on spike protein and 7b gene of feline infectious peritonitis virus: Influences of viral replication in monocytes/macrophages and virulence in cats , 2011, Virus Research.
[66] Torsten Schwede,et al. Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective , 2009, Electrophoresis.
[67] T. Takano,et al. Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. , 2008, The Journal of veterinary medical science.
[68] Taehoon Kim,et al. CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..
[69] René Thomsen,et al. MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.
[70] Kwanyee Leung,et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[71] H. Pearson. Caution raised over SARS vaccine , 2005, Nature.
[72] Y. Kawaoka,et al. Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.
[73] Shinji Watanabe,et al. Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein , 2001, Journal of Virology.
[74] D. Morens,et al. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[75] M. Froimowitz,et al. HyperChem: a software package for computational chemistry and molecular modeling. , 1993, BioTechniques.
[76] H. Vennema,et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization , 1990, Journal of virology.
[77] S. Halstead,et al. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. , 1973, The Journal of infectious diseases.
[78] S. Halstead,et al. Hemorrhagic fever in Thailand; recent knowledge regarding etiology. , 1967, Japanese journal of medical science & biology.
[79] J. Orient. Negative Evidence : Antibody-Dependent Enhancement , 2022 .
[80] H. Arase,et al. [Infectivity-enhancing antibodies against SARS-CoV-2]. , 2021, Uirusu.
[81] P. V. Bramhachari. Dynamics of Immune Activation in Viral Diseases , 2020 .
[82] J. Fantini,et al. Hybrid In Silico/In Vitro Approaches for the Identification of Functional Cholesterol-Binding Domains in Membrane Proteins. , 2017, Methods in molecular biology.
[83] K. Yoon,et al. Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.